Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in France / NCT06993987
Active, not recruiting Observational

Study of Interactions Between Oncologists and Resuscitators to Optimize Decision Making for Admission of Patients With Metastatic Solid Cancer to the ICU (InterOncoRea)

NCT06993987 · tracked via the Priya Life Science France tracker
Sponsor
University Hospital, Brest
Phase
Observational
Started
2025-03-01
Last updated
2025-05-29

Condition(s) studied

Intensive Care Unit (ICU) PatientsMetastatic Cancer

Investigational drug(s) / intervention(s)

Descriptive analysis

Descriptive analysis: The descriptive analysis of qualitative variables (reason for admission) will be carried out in the form of frequencies and percentages. Quantitative variables will be described in terms of averages, medians or standard deviations, as required.

Study summary

The aim of our study is to optimise the interaction between oncologists and resuscitators to improve decision-making regarding the admission of patients with metastatic solid cancers to the ICU.

The study is structured into two successive stages. The first stage involves a retrospective descriptive analysis of patients with metastatic solid cancer admitted to the ICU, to enable comparison with centres that have already documented this subject.

The second stage involves personalised interviews with medical staff working in both the oncology department and the intensive care unit.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Major patient hospitalized in medical or surgical intensive care with metastatic solid cancer, whatever the primary site and whatever the reason for admission to the intensive care unit * Start of stay in intensive care must be between June 1, 2023 and June 1, 2024. Exclusion Criteria: * Patient objecting to data processing * The patient is under legal protection (e.g. guardianship or curatorship) * A patient with multiple synchronous cancers * Diagnosis of metastatic cancer during stay in intensive care unit intensive care unit

Primary outcome measure(s)

  • Frequency of reason for admission to intensive care unit — Patients admitted to intensive care between June 1, 2023 and June 1, 2024.
    Analysis of the reason for admission to intensive care unit

Trial sites (1)

FacilityCityRegionStatus
Chu Brest Brest France

More University Hospital, Brest trials in France

Risk Factors of Venous Thromboembolism in Women During Hormonal Exposure Recruiting
Shared Decision-making Process for Unprovoked vEnous THromboEmbolism Management. (ETHER ) Recruiting
Establishment of a Patient Library in Patients With Pruritus Sine Materia Recruiting
Recurrence of Thromboembolic Venous Disease of Atypical Location (RUSE) Active, not recruiting
Platelet Activity Monitoring for Patients Under Adp Medication Using Verify Now in Subdural Hematoma Starting soon

Other trials for the same condition

Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21) Active, not recruiting
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors Recruiting
A Study to Provide Continued Access to and Assess Long-Term Safety of the Study Drug(s) Recruiting
Implementing Precision Medicine in cOmmunity HospiTALs Recruiting
First-in-human Trial of PhOx430, a First-in-class Acetylglucosaminyltransferase V Inhibitor, in Advanced Solid Tumours Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06993987 on ClinicalTrials.gov ↗ ← All trials in France